Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int Urol Nephrol ; 55(3): 529-539, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36464759

ABSTRACT

PURPOSE: Tomato is an important source of lycopene, a carotenoid that has been emerging as a natural preventive agent for prostate disease. Moreover, tomato contains other components with a wide range of physiological properties, but their potential beneficial effects on prostatic hyperplasia (PH) during obesity have not been completely established. In this study, we compared the effect of a lipidic extract of tomato saladette (STE) with Serenoa repens (SR) on obese rats with PH. METHODS: Forty-eight Wistar rats were divided in Control (C) and Obese (Ob) treated without (n = 12) and with (n = 36) testosterone enanthate (TE), once a week for 8 weeks to induce PH. After 4 weeks, SR and STE were administered. Biochemical parameters, oxidative stress markers and inflammatory cytokines production were determined. RESULTS: TE increased prostate weight and caused prostatic hyperplasia in C group, and these effects were exacerbated by obesity. SR and STE reverted the increase in prostate weight and hyperplasia caused by TE in C and Ob groups. Obesity increased LDL, TGs, NOx and MAD, but decreased HDLc, GSx, SOD and CAT. SR reverted the effects of obesity, but these were significantly reduced and HDLc increased with STE. Obesity and TE increased TNFα, IL-1ß and IL-6 levels, but these were partially reverted by STE compared with SR. CONCLUSIONS: Excess of fat tissue increases the alterations by PH. STE diminishes these alterations compared with SR, suggesting its beneficial effect to improve prostate function. Whole tomato lipid extract could serve as sole therapy or as an adjunct to pharmacological treatment for PH.


Subject(s)
Prostatic Hyperplasia , Solanum lycopersicum , Male , Humans , Rats , Animals , Prostatic Hyperplasia/drug therapy , Hyperplasia , Rats, Wistar , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Testosterone/therapeutic use , Oxidative Stress , Inflammation/drug therapy , Obesity
2.
J Sci Food Agric ; 100(7): 3212-3219, 2020 May.
Article in English | MEDLINE | ID: mdl-32105339

ABSTRACT

BACKGROUND: The aim of this study was to evaluate the effects of capsaicin (Cap), moderate exercise (Ex), and their combination on arterial blood pressure (BP) and metabolic complications in hypoestrogenic (HE) obese (HEOb) rats. Female Wistar rats were ovariectomized and given 300 g L-1 sucrose solution (HEOb), or purified water (HE) ad libitum, for 28 weeks. After shaving the abdominal skin, cold cream vehicle was applied to sedentary (Sed) and exercise (Ex) groups, and 0.75 g kg-1 Cap cream was applied to Ex groups. Ex groups ran on a treadmill every day for 20 min at speeds from 0.15 to 0.3 m s-1 . For combination groups (Cap + Ex), topical Cap was applied 90 min before Ex. The treatments were performed for 6 weeks, and BP was recorded before and at the end of the experimental protocol. The animals were killed by decapitation, and blood and tissues were obtained to perform oxidative profile, as well as to undertake biochemical and histologic studies. RESULTS: Compared with individual treatments, the combined therapy (Cap + Ex) in HEOb rats caused a higher reduction in the caloric intake, body weight, abdominal fat percentage, oxidative stress, and hepatic steatosis. In HEOb groups, Cap was the only treatment that reduced BP and prevented dyslipidemia and oxidative stress. CONCLUSION: The present data show that Cap improves the metabolic alterations induced by obesity and hypoestrogenism, suggesting that Cap can be considered as an excellent candidate for therapy of these clinical conditions. © 2020 Society of Chemical Industry.


Subject(s)
Capsaicin/administration & dosage , Dyslipidemias/prevention & control , Estrogens/blood , Exercise Therapy , Fatty Liver/prevention & control , Obesity/complications , Obesity/therapy , Animals , Blood Pressure/drug effects , Combined Modality Therapy , Female , Humans , Male , Obesity/blood , Obesity/drug therapy , Rats , Rats, Wistar , Skin Cream/administration & dosage
3.
Res Social Adm Pharm ; 15(3): 321-329, 2019 03.
Article in English | MEDLINE | ID: mdl-29731375

ABSTRACT

BACKGROUND: In Mexico, the Modelo Nacional de Farmacia Hospitalaria (MNFH, or National Hospital Pharmacy Model), published in 2009, mainly aims to promote the provision of clinical pharmacy services in private and public hospitals. However, there is little scientific documentation about the quality of these services. OBJECTIVES: To explore healthcare professionals' perceptions related to the quality of clinical pharmacy services provision. METHODS: A case-study based on a qualitative approach was performed at the pharmaceutical services unit at a public hospital located in Mexico City, which operates under the administrative control of the Ministry of Health. Donabedian's conceptual model was adapted to explore health care professionals' perceptions of the quality of clinical pharmacy services provision. Semi-structured interviews were carried out with pharmacists, physicians and nurses and then transcribed and analyzed via discourse analysis and codification techniques, using the software package Atlas. ti. RESULTS: Limitations in pharmaceutical human resources were identified as the main factor affecting coverage and quality in clinical pharmacy services provision. However, the development in pharmacy staff of technical competences and skills for clinical pharmacy service provision were recognized. Significant improvements in the rational use of medicines were associated with clinical pharmacy services provision. CONCLUSIONS: The perception analysis performed in this study suggested that it is necessary to increase pharmacy staff in order to improve interprofessional relationships and the quality of clinical pharmacy services provision.


Subject(s)
Health Personnel/psychology , Pharmacy Service, Hospital , Attitude of Health Personnel , Hospitals, Public , Humans , Interprofessional Relations , Mexico , Perception , Pharmacists , Quality of Health Care
4.
J Sci Food Agric ; 97(13): 4451-4458, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28276068

ABSTRACT

BACKGROUND: Obesity is associated with increased risk of a number of serious medical conditions, including urological disorders. This study investigated the effect of lipidic extracts of saladette tomato pomace (STP) and Serenoa repens (SR) on the prostate and bladder in a rat obese model induced by high-carbohydrate diet. RESULTS: High-sucrose-fed rats showed higher prostate weight as well as increased contractility and stromal and epithelial hyperplasia in the prostate. Treatment with STP and SR improved contractility and diminished hyperplasia and hypertrophy in the prostate. Obese animals also showed impaired bladder contractility, but neither extract reversed this deterioration. In the histological study, a disarray in the process of smooth muscle cell proliferation with non-parallel fibers was observed; interestingly, treatment with STP and SR led to improvement in this derangement. CONCLUSION: These findings indicated impaired contractility and hyperplasia in the prostate and bladder of obese rats induced by high sucrose. STP and SR could enhance prostate function by reducing contractility and hyperplasia and improve smooth muscle fiber structure and decrease cell proliferation in the bladder, suggesting their possible health-beneficial effects on lower urinary tract symptoms. © 2017 Society of Chemical Industry.


Subject(s)
Obesity/complications , Plant Extracts/administration & dosage , Prostate/drug effects , Serenoa/chemistry , Solanum lycopersicum/chemistry , Urinary Bladder/drug effects , Animals , Humans , Male , Obesity/metabolism , Prostate/physiopathology , Prostatic Diseases/drug therapy , Prostatic Diseases/etiology , Prostatic Diseases/metabolism , Prostatic Diseases/physiopathology , Rats , Rats, Wistar , Urinary Bladder/physiopathology , Urinary Bladder Diseases/drug therapy , Urinary Bladder Diseases/etiology , Urinary Bladder Diseases/metabolism , Urinary Bladder Diseases/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...